Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: Preliminary data of an open-label study

Loredana Dinapoli, Marta Maschio, Bruno Jandolo, Alessandra Fabi, Andrea Pace, Francesca Sperati, Paola Muti

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this pilot study was to investigate the effects of levetiracetam monotherapy on seizure control, quality of life and neurocognitive performance in patients with brain tumor-related epilepsy. We present here preliminary data from 18 patients with follow-up of 6 months. We evaluated seizure frequency at baseline. We used administered Mini Mental State Examination (MMSE), Karnofsky Performance Status (KPS), Barthel index (BI), QOLIE 31P (V2), EORTC QLQ-C30 and Adverse Events Profile. After 6 months, 16 patients were seizure free (88.9%), 2 (11.1%) had reduction in seizure frequency >50%. Compared to baseline, we observed a worsening of performance (KPS p = 0.011; BI = 0.008) and global lower cognitive performance (MMSE p = 0.011); distress related to seizure frequency (p = 0.003) and medication effects (p = 0.046) were significantly lower. Levetiracetam caused mild and reversible side effects. These preliminary data on LEV monotherapy in patients with brain tumor-related epilepsy show that this antiepileptic drug is efficacious and well tolerated.

Original languageEnglish
Pages (from-to)353-359
Number of pages7
JournalNeurological Sciences
Volume30
Issue number4
DOIs
Publication statusPublished - 2009

Keywords

  • Brain tumor-related epilepsy
  • Efficacy
  • Levetiracetam
  • Quality of life

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Fingerprint Dive into the research topics of 'Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: Preliminary data of an open-label study'. Together they form a unique fingerprint.

Cite this